gene knockdown

LIPC siRNA (Human)

MBS8214360

15 nmol

365 USD

siRNA

LIPC siRNA (Human)

[LIPC]

[HTGL; Hepatic triacylglycerol lipase; HL; Hepatic lipase; Lipase member C]

[hepatic triacylglycerol lipase; Hepatic triacylglycerol lipase; hepatic triacylglycerol lipase; lipase, hepatic; Lipase member C]

[LIPC]

[LIPC; LIPC; HL; HTGL; LIPH; HDLCQ12; HTGL; HL; Hepatic lipase]

LIPC_HUMAN

Synthetic

Human

499

LIPC siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.

> 97%

Lyophilized powder

Shipping: Blue ice. Store at -20°C for one year.

RNA Interference (RNAi)

Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency. Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well). Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human LIPC gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.

siRNA to inhibit LIPC expression using RNA interference

194097335

NP_000227.2

NM_000236.2

P11150

Acylglycerol Degradation Pathway (413388); Acylglycerol Degradation Pathway (468272); Chylomicron-mediated Lipid Transport Pathway (1270006); Fatty Acid Beta Oxidation Pathway (198865); Glycerolipid Metabolism Pathway (82986); Glycerolipid Metabolism Pathway (361); Lipid Digestion, Mobilization, And Transport Pathway (1270002); Lipoprotein Metabolism Pathway (1270005); Metabolic Pathways (132956); Metabolism Pathway (1269956)

LIPC encodes hepatic triglyceride lipase, which is expressed in liver. LIPC has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. [provided by RefSeq, Jul 2008]

LIPC: Hepatic lipase has the capacity to catalyze hydrolysis of phospholipids, mono-, di-, and triglycerides, and acyl-CoA thioesters. It is an important enzyme in HDL metabolism. Hepatic lipase binds heparin. Defects in LIPC are the cause of hepatic lipase deficiency (HL deficiency). A disorder characterized by elevated levels of beta-migrating very low density lipoproteins, and abnormally triglyceride-rich low and high density lipoproteins. Belongs to the AB hydrolase superfamily. Lipase family. Protein type: Secreted; EC 3.1.1.3; Phospholipase; Secreted, signal peptide; Lipid Metabolism - glycerolipid. Chromosomal Location of Human Ortholog: 15q21-q23. Cellular Component: extracellular space. Molecular Function: heparin binding; triacylglycerol lipase activity; low-density lipoprotein binding; apolipoprotein binding; phospholipase activity. Biological Process: cholesterol metabolic process; cholesterol homeostasis; reverse cholesterol transport; triacylglycerol catabolic process; fatty acid biosynthetic process. Disease: High Density Lipoprotein Cholesterol Level Quantitative Trait Locus 12; Hepatic Lipase Deficiency; Diabetes Mellitus, Noninsulin-dependent

15 nmol

365 USD

30 nmol

515